Home Business & Finance Novo Nordisk shares dive 9% after heart medicine fails trial
Business & Finance

Novo Nordisk shares dive 9% after heart medicine fails trial

Key Points

Shares of Novo Nordisk nosedived as much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to placebo. This is breaking news. Please refresh for updates.

Shares of Novo Nordisk nosedived as much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to placebo. This is breaking news. Please refresh for updates. Shares of Novo Nordisk nosedived as much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to placebo. This is breaking news. Please refresh for updates.
Novo Nordisk (ORG)
Originally published by CNBC Read original →